Nadia Agopyan

Nadia Agopyan, Ph.D., RAC, is an accomplished professional in regulatory affairs with extensive experience in the biopharmaceutical industry. Currently serving as Senior Vice President at Neurona Therapeutics since March 2024, Nadia previously held the position of Senior Vice President and Head of Regulatory Affairs at Marker Therapeutics, Inc., where efforts focused on developing T cell therapies for treating solid tumors and hematological malignancies. Notably, Nadia played a pivotal role at Kite Pharma, Inc. managing global regulatory affairs for Yescarta, and led key approvals at Baxter Bioscience for recombinant therapies. With substantial expertise gained through roles at Ambit Biosciences, Johnson and Johnson, Cougar Biotechnology, and Amgen, Nadia possesses a robust academic background with a Ph.D. in Physiology/Neurophysiology from McGill University.